# GLP-1 Drugs After 65: Strength, Not Just Weight

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-11-10

Canonical page: https://glpwatchdog.org/research/glp1-after-65-strength-and-frailty

> Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and a 2024 review found no concise guidelines for this age group.

## Key points

- General adult trials: grip strength statistically preserved despite lean mass falling.
- Older adults with type 2 diabetes, prolonged use: reduced grip strength, accelerated sarcopenia.
- Lean mass has been reported as 15–40% of total weight lost in high-risk groups.
- A 2024 review found no concise guidelines for prescribing these drugs after 65.

The reassuring finding about muscle comes from trials in general adult populations, and it is real. [Handgrip strength has held up](https://glpwatchdog.org/research/handgrip-strength-and-sarcopenic-obesity) in short and medium-term trials of semaglutide and liraglutide even while lean soft tissue fell.[1] The trouble is that the picture changes in the group most likely to be harmed by muscle loss. Longitudinal and retrospective research in **older adults with type 2 diabetes** reports the opposite: reduced grip strength and accelerated sarcopenia with prolonged semaglutide use.[1] A 2024 review found no concise guidelines for prescribing these drugs after 65.[3] The studies that do include older adults, none of them designed around them, are gathered in [our after-65 reading list](https://glpwatchdog.org/research/lists/top-glp1-older-adults-studies).

## Mass and strength are not the same measurement

Most of the argument about muscle on these drugs is about mass, because mass is what a DXA scanner measures and what body-composition substudies report. Our [lean mass article](https://glpwatchdog.org/research/glp1-hair-loss-and-muscle-loss) works through that evidence, and the short version is more reassuring than the headlines: lean tissue accounts for roughly a quarter to a third of weight lost, and intensive lifestyle programs cost a comparable share.

Strength is a different variable. It is what decides whether someone can rise from a chair without using their arms, carry shopping, or recover a stumble instead of falling. Grip strength is the standard proxy, and it is one of the defining components of [sarcopenia](https://glpwatchdog.org/glossary/sarcopenia) in its own right.

> Strength decides whether someone can rise from a chair without using their arms.

## What the strength evidence shows, by age

*Summarized from a 2026 review of GLP-1 drugs and muscle strength. All of it is short-to-mid-term or observational; no trial has been designed around this question in older adults.*

| Population | What was observed |
| --- | --- |
| Adults with obesity, short to mid-term trials | Grip strength **statistically preserved** despite reductions in lean soft-tissue mass — strength did not fall in proportion to weight[1] |
| **Older adults with type 2 diabetes, prolonged use** | **Reduced grip strength and accelerated sarcopenia** in longitudinal and retrospective research[1] |

Two things separate the last row from the first. One is age, and the fact that muscle mass and strength are already declining before any drug is involved. The other is duration: the reassuring results come from short and medium-term trials, and the concerning ones from prolonged use. A treatment intended to continue indefinitely is not well described by a 68-week trial.

> **These are observational findings, and that cuts both ways.** Retrospective data in older adults with diabetes cannot separate the drug from the aging, the diabetes, or the illness that prompted the prescription. It is a signal worth taking seriously, not a settled result, and it argues for running the trial instead of for either reassurance or alarm.

## Who carries the most risk

A 2025 review looked at the groups already predisposed to sarcopenia before a GLP-1 enters the picture, and made the obvious but under-stated point: the same proportional loss lands harder on someone with less reserve.[2] It puts lean mass at as much as 15 to 40% of total weight lost, and notes that evidence on body composition is *insufficient* in older adults, and equally so in chronic kidney disease, liver disease and [inflammatory bowel disease](https://glpwatchdog.org/research/glp1-and-inflammatory-bowel-disease).

- **Anyone already frail, or recently hospitalized.** Reserve is the variable, not percentage lost.
- **Anyone with sarcopenic obesity** (high fat and low muscle together). It is common after 65 and easy to miss because the scale looks like a straightforward obesity problem.[3]
- **Anyone eating substantially less than they were.** The appetite suppression that drives the weight loss can also undercut protein intake, at the age when protein matters most.
- **Anyone not doing resistance work.** The reviews agree on this even where they agree on little else.

## What is actually recommended, and by whom

A 2024 review of obesity pharmacotherapy in adults 65 and over found the general-population efficacy and safety data increasingly favorable, but concise guidelines for older adults unavailable.[3] It calls for trials that measure geriatric outcomes rather than weight alone.

So a prescriber weighing this for someone in their seventies is extrapolating from trials whose average participant was decades younger, without a guideline to work from. An effective drug can still be the right call for an older patient, but the usual scaffolding is missing, so it is worth asking what is being monitored instead.

The reviews do converge on two unglamorous things: adequate protein, and [resistance training](https://glpwatchdog.org/research/qna/top-glp1-exercise-workout-questions-reddit-answered), from the start rather than after a loss.[2] Our [protein calculator](https://glpwatchdog.org/tools/glp1-protein-calculator) works a target from body weight, and the [exercise pairing tool](https://glpwatchdog.org/tools/glp1-exercise-pairing-configurator) sets out the training side. For the same question framed around the menopausal transition rather than age 65, see [GLP-1 drugs after menopause](https://glpwatchdog.org/research/glp1-after-menopause).

## Frequently asked questions

### Are GLP-1 drugs safe for people over 65?

The general-population efficacy and safety data are increasingly favorable, but a 2024 review found no concise guidelines written for this age group, and trials measuring geriatric outcomes rather than weight are what reviewers keep asking for. A prescriber is extrapolating from trials whose participants were decades younger.

### Do these drugs weaken muscle in older adults?

The evidence splits by age. Short-to-mid-term trials in adults with obesity found grip strength statistically preserved despite lean mass falling. Longitudinal and retrospective research in older adults with type 2 diabetes reported reduced grip strength and accelerated sarcopenia with prolonged use. The second set is observational and cannot separate the drug from aging or diabetes.

### Is losing muscle mass the same as getting weaker?

Not necessarily, and that is the useful part. Mass is what a DXA scanner measures; strength is what determines whether someone can rise from a chair or recover a stumble. In several trials strength held up better than mass did, which is why grip strength is worth asking about rather than body composition alone.

### What reduces the risk?

The reviews converge on adequate protein intake and resistance training, started alongside the drug rather than after a loss has happened. That is consistent advice across sources that disagree about much else.

### Should an older adult avoid these drugs?

Nothing here says that, and obesity in later life carries its own serious costs. The argument is about measuring strength and function, not only the number on the scale, and about knowing that the guideline scaffolding a prescriber would normally rely on was still missing for this age group as of 2024.

## References

1. Prokopidis K. Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions. British Journal of Pharmacology. 2026. PMID: 41577337. https://pubmed.ncbi.nlm.nih.gov/41577337/
2. Memel Z, Gold SL, Pearlman M, et al. Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia. Current Nutrition Reports. 2025. PMID: 40289060. https://pubmed.ncbi.nlm.nih.gov/40289060/
3. Žižka O, Haluzík M, Jude EB. Pharmacological Treatment of Obesity in Older Adults. Drugs & Aging. 2024. PMID: 39514148. https://pubmed.ncbi.nlm.nih.gov/39514148/

---

Cite as: GLP Watchdog, Ruth Calder, "GLP-1 Drugs After 65: Strength, Not Just Weight", published 2026-08-19, updated 2026-11-10. https://glpwatchdog.org/research/glp1-after-65-strength-and-frailty

Canonical HTML page: https://glpwatchdog.org/research/glp1-after-65-strength-and-frailty

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
